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Introduction HIV infection distributes to a variety of anatomic sites including but not limited to the circulatory system, central nervous system (CNS), genital tracts, lymphatic system and intracellular compartments. Antiretroviral drugs (ARVs) have been highly effective in the treatment of HIV through suppression of viral replication; however, there is a lack of understanding in ARV distribution beyond the blood plasma thereby limiting our ability to evaluate extravascular efficacy and/or toxicity. A major anatomical site of concern in the treatment of HIV is the CNS since the virus is known to distribute to this compartment yet many ARVs exhibit poor penetration into the cerebrospinal fluid (Letendre S and et al., 2008; Dellamonica et al., 2012) . HIV associated neurological disease is relatively common, resulting in significant cognitive and neurological impairment, however the etiology is incompletely understood (Resnick et al., 1988; Sacktor, 2002; McArthur, 2004; Valcour et al., 2012) . The male genital tract has also shown poor ARV penetration (Kashuba et al., 1999; Avery et al., 2011) and is a compartment of concern in that it is the primary site of transmission through HIVladen semen (Resnick et al., 1988; Stekler et al., 2008; HIV/AIDS, 2009) . Although the ability of ARVs to penetrate these compartments is an important aspect of HIV therapy, in many cases, a comprehensive understanding of the distribution of these drugs beyond the blood is lacking.
One of the better characterized drugs in this regard is the non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) that has been demonstrated to penetrate, though minimally, both the male genital tract and CNS. Recent reports have revealed that there exists a 150-fold total concentration gradient for EFV from blood plasma to cerebrospinal fluid (Best et al., 2011 ) and 20-fold from blood plasma to seminal plasma (Avery et al., 2011) . 
5 which is the major oxygenated metabolite of efavirenz and is formed by CYP2B6 (Ward et al., 2003; Bumpus et al., 2006) . EFV is also metabolized to a lesser extent to 7-hydroxy efavirenz (7-OH EFV) and 8,14-hydroxy efavirenz (8,14-OH EFV) that are formed by CYP2A6 and CYP2B6, respectively (Mutlib et al., 1999; Bumpus et al., 2006; Ogburn et al., 2010) . In addition, EFV is an autoinducer of metabolism in that it increases expression of CYP2B6 through activation of the constitutive androstane receptor (Faucette et al., 2007) . These enzymes have been shown to be detectable in both the blood brain barrier and the prostate suggesting the possibility for local metabolism of EFV in the central nervous system and male genital tract (Finnström et al., 2001; Miksys and Tyndale, 2002; Kumagai et al., 2007) . Thus, the studies herein were designed to gain an understanding of the distribution of metabolites of EFV in the blood plasma, seminal plasma and cerebrospinal fluid while also examining their anti-HIV activity. As such, the following novel findings are reported: 1) mono-and di-oxygenated metabolites of EFV are present at similar levels in seminal plasma and blood plasma; 2) proteinfree EFV metabolite concentrations were only present in seminal plasma and presented with different degrees of protein binding compared to blood plasma; 3) mono-and di-oxygenated EFV metabolites are not pharmacologically active towards HIV; 4) a previously unreported dihydroxylated metabolite of EFV that appears to be seminal plasma specific was detected.
Taken together, this study is the first, to the best of our knowledge, to report the physiological distribution of metabolites of an ARV into relevant biological compartments and to examine their anti-HIV activity. Further, these data suggest that the male genital tract may be a novel compartment that should be considered in working to gain a comprehensive understanding of drug metabolite exposure.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods

Subjects and demographic characteristics
Archived blood plasma and cerebrospinal fluid samples were received from a previous study (Tovar-y-Romo et al., 2012) , and analyzed for total and protein-free EFV and EFV metabolite concentrations. The study involved 13 total participants on a once daily dosing regimen containing EFV, where paired blood plasma and cerebrospinal fluid samples were obtained. All subjects had been taking EFV for a minimum of 4 weeks prior to study enrollment. The 13 total research participants ranged in age from 37 to 71 years old, of which 2 were women and 11 were men, and 1 was European American and 12 were African American.
Archived blood plasma and seminal plasma samples were obtained from an additional previous study (Cao et al., 2007) and analyzed for total and protein-free EFV and EFV metabolite concentrations. The original study involved 6 total research participants who provided paired blood and semen samples at multiple time points throughout a 5 day study. Research participants on 600mg daily EFV were changed to a 100mg EFV every 4 hour regimen to establish near true steady-state conditions due to the estimated 40-55 hour EFV half-life and frequent dosing interval. The six men enrolled ranged in age from 33 to 48 years old, of which 1 was European American and 5 were African American.
Each of these studies was approved by the Johns Hopkins Medicine Institutional Review
Board and all research participants provided informed consent for participation. Sciences) using modifications of previously published methods (Radesca et al., 1997; U.S.FDA, 2001 ). EFV, 8-OH EFV, 7-OH EFV and 8,14-OH EFV were dissolved in DMSO for infectivity assays and in acetonitrile for metabolism assays and stored at -20°C. Concentrations of solvent vehicles were less than 0.1% in all experiments.
Materials
Separation of Protein-free from Protein-Bound by Ultrafiltration
Separation of protein-free from protein bound was performed according to a previously described method (Avery et al., 2011) . Briefly, ultrafiltration of samples was performed using 96 well plates with a 10kDa filter membrane (Millipore, Billerica, MA, USA). Blank blood plasma for quality control preparation and method development was obtained from Biological Specialty Corporation (Colmar, PA, USA). Blank seminal plasma was obtained from Bioreclamation, Inc.
(Westbury, NY, USA). To each well of the ultrafiltration plate, 100 µl of sample was added.
Samples were incubated for one hour at 37ºC. The plates were centrifuged at 15 minute intervals for 45 minutes at 37 ºC. At every 15 minute interval, the filtrate was collected in a v-bottom 96 well collection plate and extracted with methanol. Filtrate samples were then analyzed for EFV and EFV metabolite concentrations by ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). The free EFV concentration in the clinical samples evaluated at the three centrifugation time points were used to generate an EFV concentration vs. 
Infectivity Assay
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using ficoll-paque PLUS (GE Healthcare Biosciences; Piscataway, NJ), according to the manufacturer's instructions. Isolated cells were resuspended in a stimulation medium of RPMI 1640 supplemented with 10% FBS (Invitrogen, Grand Island, NY), 100U/mL interleukin-2 (IL-2, Proleukin), Penicillin/Streptomycin, and activated with 0.5µg/mL phytohemagglutinin (PHA) (Fisher Scientific; Pittsburgh, PA). Cell suspensions were incubated for 3 days at 37°C and 5% CO 2 . CD4+ T cells were isolated using magnetic activated cell sorting (MACS) CD4+ T cell isolation kit (Miltenyi Biotec; Cambridge, MA) according to the manufacturer's instructions.
Inhibition of HIV-1 infection was measured using a modification of a previously established method using an HIV-1 reporter virus expressing an Env-green fluorescent fusion protein (GFP) (Zhang et al., 2004; Shen et al., 2008; Sampah et al., 2011; Jilek et al., 2012) . 
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9 fraction of virus infection events unaffected by drug (f u ). Infectivity is determined relative to the positive control (HIV-GFP virus only, no drug) and negative control (no virus, no drug) for each sample set. The data from infectivity experiments is calculated as follows:
Metabolism Assays
To analyze metabolite formation, EFV, 8-OH EFV, and 7-OH EFV were incubated at 5 µM or 20 µM with human liver microsomes (HLM) (50 donor pool; BD Biosciences, San Jose,CA ) as well as cDNA expressed individual human cytochromes P450 (BD Biosciences; CYP1A1, -1A2, -2A6, -2B6, -2C8, -2C9, -2C19, -2D6, -3A4, -3A5, and -3A7). The final concentration of cDNA expressed P450s and HLM were 20 pmol/mL and 1mg/mL, respectively. The final reaction volumes for assays performed using cDNA expressed P450s and HLM were 100 µL and 500 µL, respectively. Following a 5 minute equilibration period in 100mM potassium phosphate buffer (pH7.4) at 37°C, the reaction was initiated by addition of an NADPH regenerating system (BD Biosciences). The reaction was incubated for 60 minutes at 37°C. All reactions were terminated by the addition of acetonitrile. Metabolite products were extracted using a liquid: liquid extraction method, where 600 µl of 50mM Ammonium Formate was added to the reaction mixture, followed by 900 µl of Hexane:Ethyl Acetate (1:1). The reaction mixture was vortexed, centrifuged at 3000xg for 10 minutes at 4°C, and the organic layer was aliquoted into a separate tube. The organic layer was evaporated to dryness under nitrogen gas, the residue was reconstituted in 200 µl of methanol and 5µl was injected for UPLC-MS/MS analysis.
UPLC-MS/MS Detection of EFV and Metabolites
EFV and EFV metabolites were detected and quantified using a UPLC-MS/MS assay performed on an AB Sciex QTRAP ® 5500 (AB Sciex, Foster City, CA) interfaced with an Acquity ® UPLC (Waters Inc., Milfdord, MA). EFV and EFV metabolite samples were analyzed according to a modification of a previously established method (Avery et al., 2010) . EFV and EFV metabolites were resolved using a reverse-phase UPLC column (2.1 × 50 mm Acquity UPLC BEH C18) with a flow rate of 0. (Mutlib et al., 1999; Ward et al., 2003) . A recent study has identified a second dihydroxylated metabolite of EFV that was observed in vivo and in vitro following incubation with either 7-or 8-OH EFV as a substrate (Ogburn et al., 2010 
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1 3 studies were performed using human liver microsomes with EFV, 7-OH EFV or 8-OH EFV as the substrate. As shown in Figure 3 , the 1.56 and 1.73 min dihydroxylated metabolites were only detectable in the reactions containing 8-OH EFV as the substrate, suggesting that formation of these metabolites involved oxygen insertion at the 8-position of EFV. By Contrast, a third metabolite was detectable at 1.92 min following incubation with EFV, 7-OH EFV, and 8-OH EFV, suggesting that formation of this metabolite may involve oxygen insertion at both the 7-position and 8-position of EFV.
In order to probe the structures of these three dihydroxylated products tandem mass spectrometry (MS/MS) was performed ( Figure 4 ). The fragmentation pattern of the 1.56 min retention time metabolite is commensurate with that of 8,14-OH EFV as previously described (Mutlib et al., 1999 respectively. The three observed dihydroxylated products exhibit highly similar fragmentation patterns; however, the fragment ion of m/z 210.0 for the 1.92 min retention time metabolite may indicate dihydroxylation on the aromatic ring as opposed to both the aromatic ring and the cyclopropyl ring. Thus, this metabolite may be a 7,8-OH EFV product as previously hypothesized (Ogburn et al., 2010) . In contrast, the m/z 168.0 fragment of the 1.73 min retention time metabolite suggests hydroxylation on the cyclopropyl ring similar to 8,14-OH EFV. Such a metabolite has yet to be reported. With this in mind, we employed cDNA-expressed P450s in order to identify the enzyme(s) involved in the formation of this product. EFV as a substrate and the formation of these products was primarily catalyzed by CYP2B6, as well as CYP1A1 to a lesser extent. The dihydroxylated metabolite retained at 1.92 minutes was formed primarily by CYP2B6 with 8-OH EFV as a substrate. In addition, this product was also detected in incubations containing CYP2B6 and CYP2C8 with substrates EFV and 7-OH EFV, respectively ( Figure 5 ). CYP2B6 has been previously demonstrated to be responsible for metabolizing EFV to 8-OH EFV and 8,14-OH EFV (Ward et al., 2003) . To summarize the formation of dihydroxylated metabolites, we propose a schematic in Figure 6 , consistent with previously determined oxidative metabolism of EFV (Mutlib et al., 1999; Ward et al., 2003; Ogburn et al., 2010) .
HIV-Inhibitory activity of EFV Metabolites
Since we were able to detect metabolites of EFV in extravascular compartments where HIV can distribute, we used a single round infectivity assay (Zhang et al., 2004; Shen et al., 2008; Sampah et al., 2011; Jilek et al., 2012) (Parkin et al., 2004) .
This article has not been copyedited and formatted. The final version may differ from this version. Interestingly, EFV has been previously demonstrated to induce compartment specific toxicities including hepatotoxicity, CNS toxicity and decreased semen quality (Sulkowski et al., 2002; Luz et al., 2003; Dieterich et al., 2004; Ciccarelli et al., 2011) . Recently, we demonstrated for the first time that 8-OH EFV has the ability to induce cytotoxicity via stimulation of mitochondrial dysfunction and activation of stress activated signaling pathways (Bumpus, 2011) .
Subsequently, toxicity of 8-OH EFV to dendritic cells of the CNS has also been reported (Tovary-Romo et al., 2012) . Although the mechanisms underlying adverse effects of EFV on semen
quality have yet to be fully elucidated it has been reported that treatment with EFV resulted in decreased motile spermatozoa and vitality, suggested to be the result of mitochondrial toxicity or direct toxicity to the cells producing spermatozoa (van Leeuwen et al., 2008; Lambert-Niclot et al., 2011) . Since 8-OH EFV has been reported to play a causal role in certain compartment specific toxicities (Bumpus, 2011; Tovar-y-Romo et al., 2012) , understanding the clinical exposure of mono-and di-hydroxylated metabolites of EFV is of importance.
We have reported previously that protein-free concentrations of EFV are in equilibrium in the blood plasma and seminal plasma resulting from different degrees of protein binding in each compartment which create the very large total drug concentration gradients (Avery et al., 2011) . This suggests that EFV distributes into the male genital tract by mechanisms of passive diffusion. By contrast, for the mono-and di-hydroxylated metabolites of EFV, we have demonstrated in this study that the protein-free metabolites do not exist in equilibrium in the two compartments, but rather are found at measurable concentrations only in the seminal plasma, and are below assay detection limits, if at all, in blood plasma and cerebrospinal fluid. Although the protein-free concentrations of EFV metabolites were not detectable in the blood plasma samples, the protein-free gradients may be estimated using the in vitro determinations of metabolite protein binding in blood plasma and median total concentration determined for each metabolite.
Protein-free 8-OH EFV, 7-OH EFFV and 8,14-OH EFV may therefore have seminal plasma:
blood plasma free drug concentration gradients as high as 145, 188, and 209-fold, respectively.
One possible explanation for these gradients would involve EFV metabolites being potential substrates for human drug transporters at the blood-testis barrier, causing an influx of these molecules within the compartment. In the event of local metabolism of EFV, this could result in reduced compartment-specific concentrations of parent compound resulting in reduced pharmacologic effect, or an increased concentration of metabolites, which, may be pharmacologically active with a desirable effect or may induce local toxicity.
While the protein binding of 8-OH EFV is similar to EFV in both blood plasma and seminal plasma, the protein binding of 7-OH EFV and 8,14-OH EFV was found to be significantly reduced compared to the parent compound. These differences suggest that chemical may be the result of protein binding, lipophilicity partitioning (logP), and/or ion trapping (Kashuba et al., 1999) . Seminal plasma, composed primarily of secretions from the prostate glands and seminal vesicles, is the main fluid assessed when analyzing the male genital tract (Klemmt and Scialli, 2005) . Weak acids have previously been demonstrated to accumulate in prostatic fluid by ion-trapping mechanisms (Winningham et al., 1968) . Mono-or dioxygenation of a compound can impact both the acid dissociation constant and lipophilicity (partition coefficient, logP) of a molecule which can have a marked impact on compound disposition (Mack and Bönisch, 1979; Kem et al., 2004) . In oxidative metabolism, the log P is typically
shown to reduce for a compound as it is transformed to be more hydrophilic (Manners et al., 1988) , which also impacts the acidity and basicity (pKa) of a compound. For EFV metabolites, it is our hypothesis that the observed seminal plasma accumulation is the result of these fundamental chemical changes to EFV resulting from primary oxidative metabolism. (Bumpus, 2011; Tovar-y-Romo et al., 2012) .
Taken together, this study is the first to demonstrate the anatomic distribution of metabolites of an ARV into relevant biological compartments and to examine their anti-HIV activity. These results suggest there may be important compartmental differences in EFV metabolite distribution, and the male genital tract may be a novel compartment in understanding local drug distribution, efficacy, and toxicity of oxidative metabolites. metabolism to 8-hydroxy-EFV catalyzed by CYP2B6 was previously established by Ward, et al. (2003) . EFV metabolism to 7-hydroxy-EFV catalyzed by CYP2A6 and to 8-14-dihydroxy-EFV catalyzed by CYP2B6 was previously established by Ogburn, et al. (2010) .
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